Family Care Hospitals Reports Q3 FY26 Results, Recommends Director Reappointments

Family Care Hospitals Limited announced its unaudited financial results for the third quarter ended December 31, 2025, along with significant board developments and corporate governance decisions. The Board of Directors convened on January 20, 2026, to approve the quarterly results and several key appointments.

Financial Performance Overview

The company's financial performance for Q3 FY26 showed challenging operational metrics across key parameters:

Financial Metric	Q3 FY26	Q3 FY25	Nine Months FY26	Nine Months FY25
Revenue from Operations	₹6.01 lakhs	₹2.83 lakhs	₹15.11 lakhs	₹788.03 lakhs
Other Income	₹2.81 lakhs	₹0.04 lakhs	₹13.22 lakhs	₹112.46 lakhs
Total Income	₹8.82 lakhs	₹2.87 lakhs	₹28.34 lakhs	₹900.48 lakhs
Net Loss	₹95.74 lakhs	₹209.59 lakhs	₹625.98 lakhs	₹4,513.59 lakhs
Basic EPS	₹(0.18)	₹(0.39)	₹(1.16)	₹(8.36)

The company's total expenses for Q3 FY26 amounted to ₹104.56 lakhs, resulting in a loss before tax of ₹95.74 lakhs. Major expense components included other expenses of ₹56.30 lakhs, depreciation of ₹22.20 lakhs, and employee benefits expense of ₹12.61 lakhs.

Board Recommendations and Director Appointments

The Nomination and Remuneration Committee and Board of Directors have recommended several key appointments for second terms:

Independent Director Reappointments

Director Details	Appointment Information
Mrs. Archana Chirawawala	Non-Executive Independent Director
DIN	09721625
Effective Date	February 28, 2026
Term Duration	5 years (second term)
Professional Background	Chartered Accountant with 20+ years experience

Director Details	Appointment Information
Mr. Sanjeev Seth	Non-Executive Independent Director
DIN	10974972
Effective Date	February 28, 2026
Term Duration	5 years (second term)
Professional Background	33 years industry experience, 16 years in sales, 17 years in marketing

Executive Director Reappointment

Director Details	Appointment Information
Mr. Suchit Raghunath Modshing	Executive Whole Time Director
DIN	10974977
Effective Date	February 28, 2026
Term Duration	5 years (second term)
Professional Background	12+ years administrative experience, Bachelor of Commerce

All three directors are not related to any existing Directors or Key Managerial Personnel of the company, and their appointments are subject to shareholder approval.

Corporate Governance and Postal Ballot Process

The Board has initiated a comprehensive postal ballot process to seek shareholder approval for the director appointments. Key decisions include:

Postal Ballot Notice: Finalized and approved by the Board
Scrutinizer Appointment: M/s. Mukesh Siroya and Co. Practicing Company Secretary
E-voting Agency: Purva Sharegistry (India) Private Limited
Cut-off Date: January 16, 2025, for determining eligible voting members

Share Warrant Allotment

During the quarter, Family Care Hospitals received ₹4.67 crores from the preferential allotment of 18,677,500 share warrants. This includes ₹4.50 crores from Dealmoney Commodities Private Limited, representing 25% of the issue price. The allotment was conducted pursuant to SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, with the balance amount to be received upon warrant exercise.

Operational Context

The company operates exclusively in the healthcare services segment, with a paid-up equity share capital of ₹5,401.48 lakhs. The financial results were reviewed by the Audit Committee and approved by the Board of Directors, with statutory auditor review completed by Rafik and Associates, Chartered Accountants. The Board meeting commenced at 3:50 PM and concluded at 6:30 PM on January 20, 2026.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-3.56%	-2.49%	-4.61%	-19.08%	-46.91%	-72.78%

Family Care Hospitals Limited has successfully completed the allotment of 1.87 crore convertible equity warrants on a preferential basis, marking the execution of its previously announced fundraising plan. The Board of Directors approved the allotment at their meeting held on December 26, 2025, along with the appointment of a new Chief Financial Officer.

Warrant Allotment Details

The company has allotted 18,677,500 convertible warrants at an issue price of ₹10.00 per warrant to investors from both promoter and non-promoter categories. The allotment follows the regulatory framework under SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

Parameter:	Details
Total Warrants Allotted:	18,677,500
Issue Price per Warrant:	₹10.00
Upfront Payment Received:	₹4.67 crores
Payment per Warrant (25%):	₹2.50
Balance Payment (75%):	₹7.50 per warrant
Number of Investors:	6

Conversion Terms and Timeline

Each warrant is convertible into one fully paid-up equity share with a face value of ₹10.00. Warrant holders have 18 months from the allotment date to exercise their conversion option by paying the balance consideration of ₹7.50 per warrant. If warrants remain unexercised within this period, they will lapse and the upfront payments will be forfeited by the company.

Leadership Enhancement

The Board appointed Mr. Rajesh Julal More as Chief Financial Officer with immediate effect from December 26, 2025. More brings comprehensive expertise in senior finance leadership with extensive experience across multiple domains including direct and indirect taxation, GST and income tax compliance, statutory audits, and regulatory filings. His proven expertise extends to financial management, budgeting, forecasting, treasury operations, cash flow management, and strategic financial planning.

Key Expertise Areas:	Details
Financial Reporting:	IFRS and GAAP-compliant reporting, MIS development
Operations Management:	Cost management, internal controls, process improvements
Technology Integration:	ERP implementation, automation, data analytics
Strategic Leadership:	Financial modeling, M&A analysis, risk management
Emerging Technologies:	AI-driven financial reporting, ESG reporting
Team Management:	Leading high-performing finance teams, change management

More is well-versed in leveraging data analytics, AI-driven financial reporting, ESG reporting, and emerging technologies to support informed decision-making and sustainable business growth. His appointment strengthens the company's financial leadership capabilities and supports its strategic growth initiatives.

Regulatory Compliance

The warrant allotment was conducted in accordance with SEBI (ICDR) Regulations 2018 and the Companies Act, 2013. The Board meeting commenced at 5:42 PM and concluded at 7:00 PM on December 26, 2025. The disclosure was signed by Suchit Raghunath Modshing, Whole Time Director (DIN: 10974977), confirming the company's commitment to regulatory compliance and transparent corporate governance practices.